17 Capital Partners’s Edwards Lifesciences EW Stock Holding History

17 Capital Partners’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.9M	Buy	20,990 +10,954	+109%	+$918K	0.86%	24
2026 Q1	$804K	Buy	10,036 +3,325	+50%	+$274K	0.41%	87
2025 Q4	$572K	Buy	+6,711	New	+$551K	0.29%	103
2022 Q3	$339K	Hold	4,108	–	–	0.46%	66
2022 Q2	$391K	Hold	4,108	–	–	0.49%	65
2022 Q1	$484K	Hold	4,108	–	–	0.5%	67
2021 Q4	$532K	Hold	4,108	–	–	0.49%	68
2021 Q3	$465K	Buy	4,108 +25	+0.6%	+$2.85K	0.44%	70
2021 Q2	$423K	Buy	+4,083	New	+$385K	0.39%	74

Other funds holding EW

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

17 Capital Partners's EW Position: Q2 2026 in Review

17 Capital Partners increased its Edwards Lifesciences (EW) stake by 109% in Q2 2026, buying an estimated $918K and bringing the position to 20,990 shares worth $1.9M. The position accounts for 0.86% of the portfolio, ranked #24.

17 Capital Partners first reported a position in EW in Q2 2021 and has held it in 9 quarters since. 1,333 funds tracked by Wall St. Rank hold EW as of Q2 2026.

17 Capital Partners held 20,990 shares of Edwards Lifesciences worth $1.9M as of Q2 2026.
17 Capital Partners bought 10,954 Edwards Lifesciences shares in Q2 2026, an estimated $918K.
Edwards Lifesciences made up 0.86% of 17 Capital Partners's portfolio in Q2 2026, its #24 holding.
17 Capital Partners first reported a position in Edwards Lifesciences in Q2 2021 and has held it in 9 quarters since.
1,333 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on 17 Capital Partners's 13F filing for Q2 2026, filed 6 Aug 2026.